| scholarly article | Q13442814 |
| P2093 | author name string | Pierre-Jean Pisella | |
| Carole Burillon | |||
| Frederic Chiambaretta | |||
| P2860 | cites work | Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. | Q50494234 |
| Diagnostic tests in the Sicca syndrome | Q70112003 | ||
| Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren's syndrome | Q83251629 | ||
| Glycyrrhizin inhibits the inflammatory response in mouse mammary epithelial cells and a mouse mastitis model | Q87606032 | ||
| Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction | Q26771284 | ||
| The pathophysiology, diagnosis, and treatment of dry eye disease | Q28083825 | ||
| Prevalence of dry eye syndrome among US women | Q28196875 | ||
| DAMPs, PAMPs and alarmins: all we need to know about danger | Q29547535 | ||
| Dry eye as a mucosal autoimmune disease | Q34647761 | ||
| Grading Of Corneal and Conjunctival Staining in the Context of Other Dry Eye Tests | Q35542950 | ||
| Alarmins: chemotactic activators of immune responses | Q36162859 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| Assessment of the tolerability profile of an ophthalmic solution of 5% glycyrrhizin and copolymer PEG/PPG on healthy volunteers and evaluation of its efficacy in the treatment of moderate to severe blepharitis | Q37015100 | ||
| Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid | Q38397138 | ||
| TFOS DEWS II pathophysiology report | Q38652987 | ||
| TFOS DEWS II Epidemiology Report | Q38652994 | ||
| TFOS DEWS II Definition and Classification Report. | Q38665717 | ||
| TFOS DEWS II Management and Therapy Report | Q39453364 | ||
| Glycyrrhizin inhibits interleukin-8 production and nuclear factor-kappaB activity in lung epithelial cells, but not through glucocorticoid receptors | Q40001843 | ||
| Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease | Q41479666 | ||
| Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities | Q42828870 | ||
| Quantitative evaluation of ocular anti-inflammatory drugs based on measurements of corneal temperature in rabbits: dexamethasone and glycyrrhizin | Q44009523 | ||
| 18β-glycyrrhetic acid inhibits immune activation triggered by HMGB1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis | Q44871874 | ||
| Effect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomography | Q48143565 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 2629-2636 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study | |
| P478 | volume | 12 |
Search more.